Contribute Try STAT+ Today

Gilead Sciences (GILD) released top-line trial data for its Yescarta medication that may allow the company to leapfrog over a rival in the marketing battle over CAR-T therapies.

The preliminary results of a randomized Phase 3 trial showed the treatment — which involves extracting white blood cells and genetically modifying them to attack cancer — prevented the return of large B-cell lymphoma better than the standard of care, which includes chemotherapy and a stem cell transplant. The study examined patients whose initial treatment had failed and given Yescarta as a so-called second-line treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment